Skip to main content
OpenTrials
Completed

NCT Number: NCT01740037

IntegRAted Chronic Care Program at Specialized AF Clinic Versus Usual CarE in Patients With Atrial Fibrillation - RACE4

Rationale: The treatment of patients with atrial fibrillation is often inadequate due to poor guideline adherence. An integrated chronic care program (ICCP) at a specialized AF-clinic was found to be superior to usual care provided by a cardiologist in terms of cardiovascular hospitalizations and cardiovascular mortality.

Hypothesis: treatment at a specialized AF clinic is superior to usual care in terms of cardiovascular mortality and cardiovascular hospitalizations, cost-effectiveness, quality of life and guideline adherence.

Objectives: primary objective is to show that an ICCP reduces cardiovascular hospitalizations and mortality.

Study design: randomized controlled trial with two study arms: usual care provided by cardiologists (control) versus integrated chronic care program at a specialized AF clinic (intervention) in 8 hospitals in the Netherlands. The RACE4 is an event driven study. A total number of 246 events is needed. In total 1716 patients with newly diagnosed AF will be included. Total duration of the study is 5 years and 10 months with a minimal follow up of 1 year. Data is collected at inclusion, after 3, 6, 12 months, every year thereafter and at the end of the study.

Study population: Patients older than 18 year with newly diagnosed AF.

Intervention: The intervention is delivered through the specialized outpatient AF clinic. The multidisciplinary team at the AF clinic consists of a nurse practitioner or physician assistant or specialised cardiovascular nurse, cardiologist, and is guided by guidelines-based decision support software program based on the applicable ESC guideline recommendations. The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Martini Ziekenhuis, Groningen, Netherlands

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with newly diagnosed AF detected on electrocardiogram (ECG), holter recordings or event recorder with a duration > 30 seconds, 3 months before inclusion or
  • Patients with a history of diagnosed AF, with no regular control at a cardiologist for AF in the last 2 years and referred by a (non-)cardiologic medical specialist for new diagnostics or therapeutic issue;
  • Age ≥18 years.

Exclusion criteria

  • No electrocardiographic objectified AF;
  • Unstable heart failure defined as NYHA IV or heart failure necessitating hospital admission < 3 months before inclusion;
  • Acute coronary syndrome (acute myocardial infarction or instable angina pectoris, with two of the following characteristics: chest pain and/ or ischemic electrocardiographic changes, and/ or cardiac enzyme rise) < 3 months before inclusion;
  • Untreated hyperthyroidism or < 3 months euthyroidism before inclusion;
  • Foreseen pacemaker, internal cardioverter defibrillator, and/ or cardiac resynchronization therapy;
  • Cardiac surgery ≤ 3 months before inclusion;
  • Planned cardiac surgery;
  • Regular control and treatment, also for AF, at another specialized outpatient cardiac clinic;
  • Patient is not able to fill in the questionnaires;
  • Participation in other clinical study.

Treatment and study plan

Specialized outpatient AF Clinic

Other

Usual Care

Other

Primary outcomes

  1. The primary endpoint is a composite of unplanned admission to the hospital for any cardiovascular reason and cardiovascular death.

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

Secondary outcomes

  1. All components of the primary endpoint

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

  2. All-cause mortality

    Time frame: Minimum of 1 year and a maximum of 5 years and 10 months

  3. Total number of unplanned all-cause hospitalizations

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

  4. Duration of unplanned all-cause hospitalizations

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

  5. Total number of unplanned cardiovascular hospitalizations

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

  6. Duration of unplanned cardiovascular hospitalizations

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

  7. Total number of unplanned hospitalizations related to atrial fibrillation

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

  8. Duration of unplanned hospitalizations related to atrial fibrillation

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

  9. Recurrent unplanned cardiovascular hospitalizations

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

  10. Costs and cost-effectiveness

    Time frame: baseline, 1 year, 2 years, 3 years

    Costs, Quality Adjusted Life Years (QALYs) and Cost-effectiveness (Incremental Cost-Effectiveness Ratio - ICER)

  11. Implementation of care

    Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months

    The extent to which the comprehensive cardiovascular treatment is in accordance with the most recent ESC guidelines Management of Atrial Fibrillation, the HF guidelines of acute and chronic heart failure and the CVD prevention guidelines

  12. Patient Quality of life

    Time frame: Baseline, 1 year, 2 years, 3 years

    General health-related QoL is measured by using the SF-36

  13. Patient Quality of life

    Time frame: Baseline, 1 year, 2 years, 3 years

    Patient's perception of severity of arrhythmia-related symptoms is measured by using the AFSS

  14. Anxiety and/ or depression

    Time frame: Baseline, 1 year, 2 years, 3 years

    HADS-NL

  15. Knowledge of AF

    Time frame: Baseline, 1 year, 2 years, 3 years

    Netherlands Knowledge Scale on AF

  16. Compliance to medication

    Time frame: Baseline, 1 year, 2 years, 3 years

    MMAS

  17. Compliance to medication

    Time frame: Baseline, 1 year, 2 years, 3 years

    To measure the level of activation of a specific individual the PAM-13 Dutch is used

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Collaborators

  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CZ Fonds
  • DSW
  • Daiichi Sankyo
  • Pfizer
  • Stichting Achmea Gezondheidszor

Registry information

Official study title

IntegRAted Chronic Care Program at a Specialized Atrial Fibrillation (AF) Clinic Versus Usual CarE in Patients With Atrial Fibrillation, an Investigator-initiated, Prospective, Randomised, Open Label, Blinded Outcome Assessment (PROBE) Controlled Multi-center Study

Acronym: RACE4

Important dates

Study start
2012
Primary completion
2018
Study completion
2018
First posted
Dec 4, 2012
Registry last updated
May 28, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.